Committed to Improving Vision in the Real World

Our Technology Press Releases
Retinal Diseases
inner eye

THERAPEUTIC AREAS

Retinal Diseases

Researching preservative-free, sustained-release implants to replace the need for repeated injections

Glaucoma
Doctor Checking Patient's Eyes

THERAPEUTIC AREAS

Glaucoma

Researching biodegradable hydrogel alternative to the lifelong burden of daily eye drops

Ophthalmic Surgery
Ophthalmic Surgery

THERAPEUTIC AREAS

Ophthalmic Surgery

Ongoing investigation of innovative ELUTYXTM technology to transform treatments in postoperative care

Hyrdro

ELUTYX™ Technology

Our ELUTYX technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.

Our Technology
Our Pipeline

Helpful Resources

Events & Presentations

Learn more about Ocular Therapeutix at upcoming events and corporate presentations

Scientific & Medical Presentations

Read the latest scientific and medical presentations on Ocular Therapeutix emerging therapies

Investor FAQ

Find answers to commonly asked questions about Ocular Therapeutix

Ocular Therapeutix is growing quickly. We offer exciting career opportunities and comprehensive benefits for talented candidates.

See All Open Positions
Careers at Ocular

Press Releases

01 | 00
December 10, 2024
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 2, 2024
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
November 26, 2024
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
November 14, 2024
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
November 13, 2024
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
November 12, 2024
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
November 6, 2024
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
October 15, 2024
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
October 9, 2024
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)